疾病修饰性症状治疗 (DMST) 大麻素在多发性硬化症患者中的潜力
Antonio Bruno1, Pietro Annovazzi2, Marinella Clerico3
1Neurology Unit, IRCCS Neuromed, Pozzilli (IS), Italy.
Current neuropharmacology
|September 16, 2024
概括
纳比西莫尔是一种大麻素治疗方法,有效地管理多发性硬化症 (MS) 和相关症状. 新兴研究表明,它还可以通过减少炎症和保护MS患者的神经元来提供疾病修饰的好处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 多发性硬化症 (MS) 管理已经从预防复发转向解决疾病进展和残留症状.
- 纳比西莫尔是一种基于大麻素的药物,已被批准用于治疗MS相关的性.
- 性加综合征 (SPS) 的概念认识到MS中的症状集群,其中大麻素可能是有益的.
研究的目的:
- 探索纳比西摩尔除了多发性硬化症的症状缓解之外的潜力.
- 评估大麻素系统调节的抗炎和神经保护作用.
- 为MS引入疾病修饰性症状治疗 (DMST) 的概念.
主要方法:
- 对MS中大麻素系统调节的临床前和临床研究的审查.
- 对纳比西莫尔对性,疼痛,膀功能障碍,睡眠和情绪障碍的影响的分析.
- 对抗炎症和神经保护机制的检查.
主要成果:
- 在SPS概念中,nabiximols有效地治疗MS相关的性和相关症状.
- 大麻素系统调节显示出显著的抗炎和神经保护性质.
- 证据支持纳比西莫尔在控制多发性硬化症的潜在作用.
结论:
- 纳比西莫尔为治疗多发性硬化症症状提供了一个有前途的治疗选择.
- 抗炎和神经保护作用表明潜在的疾病修饰作用.
- 纳比西莫尔可以被归类为一种疾病修饰性症状治疗 (DMST).
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
205
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
205
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
170
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
170
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124


